However, in a case report in Greece, the authors attempted to combine thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) and immunosuppressive therapy with IL-6 (tocilizumab) in a patient who was admitted with acute respiratory failure secondary to COVID-19 pneumonia, who later developed ALI in his lower limb digits. The gene discussed is IL6; the disease is acute respiratory distress syndrome.